Article Text

Download PDFPDF
Tumid lupus erythematosus and systemic lupus erythematosus: a rare coexistence
  1. Ailia Ali1,
  2. Alexander Woods1,
  3. Caroline Porter1 and
  4. Steven R Feldman1,2,3,4
  1. 1Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
  2. 2Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
  3. 3Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
  4. 4Department of Dermatology, University of Southern Denmark, Odense, Denmark
  1. Correspondence to Dr Ailia Ali; ailia.k.ali{at}gmail.com

Abstract

A patient diagnosed with tumid lupus erythematosus (TLE) was subsequently found to have systemic lupus erythematosus (SLE) after presenting to a tertiary care medical centre with shortness of breath and oedema. In this commentary, we discuss this patient’s presentation and the association between TLE and SLE.

  • dermatology
  • rheumatology
  • connective tissue disease
  • systemic lupus erythematosus

Statistics from Altmetric.com

Footnotes

  • Contributors AA conceived the idea of reporting on this case. AA, CP and AW wrote the manuscript, with support and edits from SRF.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SRF has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. AA, AW and CP have no conflicts to disclose.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.